L-dopa is used to treat the motor symptoms associated with Parkinson’s disease, a neurodegenerative movement disorder characterized by a loss of dopamine neurons. L-dopa is the precursor to dopamine and crosses the blood-brain barrier to increase dopamine neurotransmission. This review will focus on the findings that dopamine produced from L-dopa is mediated in part by serotonin neurons. Direct evidence will be provided that increases in dopamine cause oxidative stress and damage serotonin neurons. Similarly, chronic L-dopa produces deficits in serotonin neurotransmission, including decreases in both serotonin cell bodies within the dorsal raphe and serotonin neurotransmitter concentrations in several forebrain regions. Since serotonin is...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
SummaryImbalance between the dopamine and serotonin (5-HT) neurotransmitter systems has been implica...
The link between the anti-Parkinsonian drug L-3,4-dihydroxyphenylalanine (L-DOPA) and the serotonerg...
L-DOPA is the gold standard medication of Parkinson's disease, a neurological disorder consequent up...
Dopamine deficiency in the striatum is a central feature of Parkinson’s disease (PD). Symptomatic th...
The ability of L-dopa to relieve the motor impairments in Parkinson's disease patients declines over...
During the last decade, the serotonergic system has emerged as a key player in the appearance of L-D...
The ability of L-dopa to relieve the motor impairments in Parkinson's disease patients declines over...
During the last decade, the serotonergic system has emerged as a key player in the appearance of L-D...
Dopamine deficiency in the striatum is a central feature of Parkinson’s disease (PD). Symptomatic th...
L-DOPA-induced dyskinesias (LIDs) are one of the main motor side effects of L-DOPA therapy in Parkin...
During the last decade, the serotonergic system has emerged as a key player in the appearance of L-D...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
SummaryImbalance between the dopamine and serotonin (5-HT) neurotransmitter systems has been implica...
The link between the anti-Parkinsonian drug L-3,4-dihydroxyphenylalanine (L-DOPA) and the serotonerg...
L-DOPA is the gold standard medication of Parkinson's disease, a neurological disorder consequent up...
Dopamine deficiency in the striatum is a central feature of Parkinson’s disease (PD). Symptomatic th...
The ability of L-dopa to relieve the motor impairments in Parkinson's disease patients declines over...
During the last decade, the serotonergic system has emerged as a key player in the appearance of L-D...
The ability of L-dopa to relieve the motor impairments in Parkinson's disease patients declines over...
During the last decade, the serotonergic system has emerged as a key player in the appearance of L-D...
Dopamine deficiency in the striatum is a central feature of Parkinson’s disease (PD). Symptomatic th...
L-DOPA-induced dyskinesias (LIDs) are one of the main motor side effects of L-DOPA therapy in Parkin...
During the last decade, the serotonergic system has emerged as a key player in the appearance of L-D...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
SummaryImbalance between the dopamine and serotonin (5-HT) neurotransmitter systems has been implica...
The link between the anti-Parkinsonian drug L-3,4-dihydroxyphenylalanine (L-DOPA) and the serotonerg...